Osteoporosis secundaria. tratamiento actualizado

Cummings, 1989, Lifetime risks of hip, Colles, of vertebral fracture and coronary heart disease among White postmenopausal women, Arch Intern Med, 149, 2445, 10.1001/archinte.1989.00390110045010 Riggs, 1995, The worldwide problema of osteoporosis: insights afforded by epidemiology, Bone, 17, 505S, 10.1016/8756-3282(95)00258-4 Stein, 2003, Secondary osteoporosis, Endoc Metab Clin N Am, 32, 115, 10.1016/S0889-8529(02)00062-2 2001, NIH Consensus Development Panel on Osteoporosis Prevention Diagnosis and Theraphy, JAMA, 285, 785, 10.1001/jama.285.6.785 Tannenbaum, 2002, Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women, 87, 4431 Chiodini, 2007, Subclinical hypercortisolism among outpatients referred for osteoporosis, Ann Int Med, 147, 541, 10.7326/0003-4819-147-8-200710160-00006 Canalis, 2007, Glucocorticoid-induced osteoporosis: pathophysiology and therapy, Osteop Int, 18, 1319, 10.1007/s00198-007-0394-0 Steinbuch, 2004, Oral glucocorticoid use is associated with an increased risk of fracture, Osteop Int, 15, 323, 10.1007/s00198-003-1548-3 Ebeling, 2008, Clinical practice. Osteoporosis in men, N Engl J Med, 358, 1474, 10.1056/NEJMcp0707217 Khosla, 2003, The role of estrogens in men and androgens in women, Endocrinol Metab Clin N A, 32, 195, 10.1016/S0889-8529(02)00087-7 Ventura, 1992, Osteopenia evaluada por densitometría bifotónica. Rol de la desnutrición y el hipogonadismo, Rev Med Chile, 120, 69 Bilezikian, 2009, Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop, J Clin Endocrinol Metab, 94, 335, 10.1210/jc.2008-1763 Vadiveloo, 2011, The thyroid epidemiology, audit and research study (TEARS): Morbidity in patients with endogenous subclinical hyperthyroidism, J Clin Endocrinol Metab, 96, 1344, 10.1210/jc.2010-2693 Heemstra, 2006, The effects of thyrotropin suppresive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma, Thyroid, 16, 583, 10.1089/thy.2006.16.583 Nicodemus, 2001, Iowa Women´s Health Study. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women, Diabetes Care, 24, 1192, 10.2337/diacare.24.7.1192 Bonds, 2006, Risk of fracture in women with type 2 diabetes: the Women´s Health Initiative Observational Study, J Clin Endocrinol Metab, 91, 3349, 10.1210/jc.2006-0614 Rodriguez, 2007, Vertebral fractures, osteoporosis and vitamin D levels in chilean postmenopausal women, 135, 31 Holick, 2011, Endocrine Society Task Force. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline, J Clin Endocrinol Metab, 96, 1911, 10.1210/jc.2011-0385 Sezer, 2003, RANK ligand and osteoprotegerin in myeloma bone disease, Blood, 101, 2094, 10.1182/blood-2002-09-2684 Melton, 2005, Fracture risk with multiple mieloma: a population-based study, J Bone Miner Res, 20, 487, 10.1359/JBMR.041131 Pumarino, 1994, Osteopenia en cirrosis biliar primaria, Rev Med Chile, 122, 1398 Stenson, 2005, Increased prevalence of celiac disease and need for routine screening among patients with osteoporosis, Arch Int Med, 165, 393, 10.1001/archinte.165.4.393 Wang, 2009, The effects of obesity surgery on bone metabolism: what orthopedic surgeons need to know, American J Ortop, 38, 77 Stein, 2007, Post-transplantation osteoporosis, Endocrinol Metab Clin N Am, 36, 937, 10.1016/j.ecl.2007.07.008 Tasca, 2002, Bone alterations in patients with idiopatic hypercalciuria, Urology, 59, 865, 10.1016/S0090-4295(02)01626-6 Tannirandorn, 2000, Drug induced bone loss, Osteop Int, 11, 637, 10.1007/s001980070062 Alibhai, 2010, Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: A matched cohort study of 19.079 men, J Urol, 184, 918, 10.1016/j.juro.2010.04.068 Schwartz, 2006, Thiazolidenione use and bone loss in older diabetes adults, J Clin Endocrinol Metab, 91, 3349, 10.1210/jc.2005-2226 Holick, 2007, Vitamin D deficiency, N Engl J Med, 357, 266, 10.1056/NEJMra070553 Oviedo S. Compromiso óseo en anorexia nerviosa. En Temas de osteoporosis y otras enfermedades óseas. Editado por Fundación Chilena de Osteoporosis. 2011 Cap.29 425-429. Reid, 2009, Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial, Lancet, 373, 1253, 10.1016/S0140-6736(09)60250-6 Grossman, 2010, American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis, Arthritis Care Res, 62, 1515, 10.1002/acr.20295 Bundred, 2008, Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal womenwith early breast cancer receiving letrozole:ZO-FAST Study results, Cancer, 112, 1001, 10.1002/cncr.23259 Michaelson, 2007, Randomized controlled trial of anual zoledronic acid to prevent gonadotropin-releasing hormone agonistinduced bone loss in men with prostate cancer, J Clin Oncol, 25, 1038, 10.1200/JCO.2006.07.3361 Ellis, 2008, Randomized trial of denosumab in patients receibing adjuvant aromatase inhibitors for nonmetastatic breast cancer, J Clin Oncol, 26, 4875, 10.1200/JCO.2008.16.3832 Smith, 2009, Denosumab in men receiving androgen-deprivation therapy for prostate cancer, N Engl J Med, 361, 745, 10.1056/NEJMoa0809003 Saag, 2007, Teriparatide or alendronate in glucocorticoid-induced osteoporosis, N Engl J Med, 357, 2028, 10.1056/NEJMoa071408